Dr. Dmitriy Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the details of immunotherapy clinical trials in ovarian cancer currently underway and new treatments in gynecologic cancers. #gynca #CRIsummit #immunotherapy summit.cancerresearch.org/
00:00- Tamron Hall introduces Dr. Dmitriy Zamarin
00:49- Dr. Zamarin discussed immunotherapy for ovarian cancer
06:28- Arthur Brodsky leads a Q&A from the audience with Dr. Zamarin
Globally, ovarian cancer is diagnosed in an estimated 300,000 women each year-and another 570,000 are diagnosed with cervical cancer and 382,000 with uterine (endometrial) cancer. While significant advances have been made in surgical and chemo-based treatments for ovarian cancer, the survival rates have only modestly improved. Immunotherapy for ovarian cancer shows tremendous potential for addressing this devastating disease. www.cancerresearch.org/Immuno...
Questions from the audience for Dr. Zamarin:
- Are there clinical trials for ovarian cancer? What is the outlook for immunotherapy for ovarian cancer?
- I have previously undergone chemotherapy and hormone therapy. Is immunotherapy an option for my cancer?
- What is the best way for a patient with recurrent ovarian cancer (BRCA 1 mutation) to learn about clinical trial options?
- What are some of the promising cancer vaccines for ovarian cancer?
- At what point should immunotherapy be sought? I'm currently doing chemo for a recurrence and this is my 3rd line of treatment. Is this a backup plan or something to coincide with chemo?
- Are there any neo-antigen vaccines for ovarian cancer available now?
- I hear that ovarian cancer is considered a cold tumor. Is there anything that a patient can do to increase the tumor immune cells such as taking prebiotics, probiotics or supplements?
- I was diagnosed with stage 4 and have had one recurrence. I am NED now. Would I be a candidate for a vaccine?
- Do genetic mutations impact these immunotherapies?
- Is it necessary to have chemotherapy before immunotherapy?
- Does Lynch syndrome increase my chances of getting ovarian cancer or endometrial cancer? Is immunotherapy the recommended treatment for cancers caused by Lynch syndrome?
- How does immunotherapy compare to chemotherapy in the longevity of "no evidence of disease" status?
Dr. Dmitriy Zamarin is a medical oncologist at Memorial Sloan Kettering Cancer Center who specializes in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers. Dr. Zamarin’s clinical and laboratory research is focused on the development of novel ways to use the immune system to treat cancer, and he is involved in clinical trials evaluating novel immunotherapy drugs in patients with cancer. www.cancerresearch.org/en-us/...
The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. www.cancerresearch.org/en-us/...
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.